Letter to the editorNitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma
References (15)
- et al.
Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma
J Allergy Clin Immunol
(2005) Nitric oxide as a clinical guide for asthma management
J Allergy Clin Immunol
(2006)- et al.
Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes
J Allergy Clin Immunol
(2006) - et al.
Partitioned exhaled nitric oxide to non-invasively assess asthma
Respir Physiol Neurobiol
(2008) - et al.
Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids
Thorax
(1998) - et al.
Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma
Am J Respir Crit Care Med
(2010) - et al.
Use of exhaled nitric oxide measurements to guide treatment in chronic asthma
N Engl J Med
(2005)
Cited by (0)
Supported by an unrestricted educational grant from GlaxoSmithKline, which also provided mepolizumab. Dr Nair holds a Canada Research Chair in Airway Inflammometry.
Disclosure of potential conflict of interest: P. Nair has received research support from GlaxoSmithKline and Ception and is listed on a patent for a sputum filtration device. P. M. O'Byrne is on the advisory board and has received speaker's honoraria from AstraZeneca and GlaxoSmithKline; is on the advisory board for Topigen, Wyeth, and Schering-Plough; and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering-Plough, and Alexion. The rest of the authors have declared that they have no conflict of interest.
Clinical Trials Identifier no. NCT00292877.